Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development.

The ability of tumor cells to invade and metastasize requires deregulation of interactions with adjacent cells and the extracellular matrix. A major challenge of cancer biology is to observe the dynamics of the proteins involved in this process in their functional and physiologic context. Here, for the first time, we have used photobleaching and photoactivation to compare the mobility of cell adhesion and plasma membrane probes in vitro and in tumors grown in mice (in vivo). We find differences between in vitro and in vivo recovery dynamics of two key molecules, the tumor suppressor E-cadherin and the membrane-targeting sequence of H-Ras. Our data show that E-cadherin dynamics are significantly faster in vivo compared with cultured cells, that the ratio of E-cadherin stabilized in cell-cell junctions is significantly higher in vivo, and that E-cadherin mobility correlates with cell migration. Moreover, quantitative imaging has allowed us to assess the effects of therapeutic intervention on E-cadherin dynamics using dasatinib, a clinically approved Src inhibitor, and show clear differences in the efficacy of drug treatment in vivo. Our results show for the first time the utility of photobleaching and photoactivation in the analysis of dynamic biomarkers in living animals. Furthermore, this work highlights critical differences in molecular dynamics in vitro and in vivo, which have important implications for the use of cultured disease models as surrogates for living tissue.

[1]  G. McLean,et al.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling , 2002, Nature Cell Biology.

[2]  James G McNally,et al.  FRAP analysis of binding: proper and fitting. , 2005, Trends in cell biology.

[3]  J. Hardin,et al.  Making and breaking contacts: the cellular biology of cadherin regulation. , 2007, Current opinion in cell biology.

[4]  O. Yizhar,et al.  Nonconventional Trafficking of Ras Associated with Ras Signal Organization , 2006, Traffic.

[5]  J. Segall,et al.  Intravital imaging of cell movement in tumours , 2003, Nature Reviews Cancer.

[6]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[7]  George H. Patterson,et al.  A Photoactivatable GFP for Selective Photolabeling of Proteins and Cells , 2002, Science.

[8]  W. Webb,et al.  Mobility measurement by analysis of fluorescence photobleaching recovery kinetics. , 1976, Biophysical journal.

[9]  O. Sansom,et al.  Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib , 2006, Molecular Cancer Therapeutics.

[10]  G. Mills,et al.  Rab25 associates with α5β1 integrin to promote invasive migration in 3D microenvironments , 2007 .

[11]  George H Patterson,et al.  Photobleaching and photoactivation: following protein dynamics in living cells. , 2003, Nature cell biology.

[12]  E. Sahai,et al.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells , 2007, Nature Cell Biology.

[13]  R. Tsien,et al.  The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.

[14]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[15]  E. Sahai,et al.  p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism , 2007, Oncogene.

[16]  J. Lippincott-Schwartz,et al.  Studying protein dynamics in living cells , 2001, Nature Reviews Molecular Cell Biology.

[17]  R. Hoffman Recent advances on in vivo imaging with fluorescent proteins. , 2008, Methods in cell biology.

[18]  Ina Weisswange,et al.  The leading edge is a lipid diffusion barrier , 2005, Journal of Cell Science.

[19]  V. Brunton,et al.  Src and focal adhesion kinase as therapeutic targets in cancer. , 2008, Current opinion in pharmacology.

[20]  Alexander Kamb,et al.  What's wrong with our cancer models? , 2005, Nature Reviews Drug Discovery.